dulaglutide vs tirzepatide cardiovascular outcome Tirzepatide in Type 2 Diabetes Patients ❇️ Cardiovascular Outcomes with Tirzepatide – Cardiovascular outcomes of semaglutide and

10.1016/S0300-483X(00)00268-7 31

The FDA Adverse Event Reporting System (FAERS), a global spontaneous reporting system, provides extensive real-world data to identify AE risk signals ( 2 Materials and methods 2.1 Data source The FAERS, accessible at is a global pharmacovigilance database that records AEs, medication errors, and product quality complaints (Yang et al., 2022)

Factors influencing results include: Starting weight Metabolic health Medication adherence Protein intake Exercise habits Medical history Our goal is not rapid weight loss but sustainable weight management and improved overall health

in addition to being effective for weight loss, Wegovy was also able to help reduce the risk of cardiovascular problems, which are common among those living with conditions like obesity and diabetes

Skipping events because of walking

Participants who made it past week 12 without stopping had an 87% chance of hitting at least 15% total weight loss by week 48